Pinned Tweet
So glad to see this work, led by my previous master student Tianao Chen, is punlished today! The tool we developed, HisToSpatialCNV can predict spatial CNVs from histopathology data alone. #informatics #deeplearning #pathology #spatialdata
HisToSpatialCNV: an interpretable deep learning method predicting spatial copy number variations from histopathology images go.nature.com/4gRLg2T
Lana Garmire 🌶 retweeted
A major breakthrough in the fight against pancreatic cancer: A recent @columbiacancer clinical trial showed a new drug nearly doubled overall survival rates for patients with previously treated metastatic pancreatic cancer. Learn more: cancer.columbia.edu/news/col…
If you are doing spatial omics research and would like to go to Big Island, Hawaii. This is your chance! Abstract is accepted in our workshop until Aug 21st, anywhere on the earth.
Together with @benjraphael , @GarmireGroup , and @Cong992, we are organizing a workshop on Multi-modal Spatial-Omics: From AI Models to Translational Applications (sites.google.com/view/multi-…) at #PSB2027. Abstract deadline is Friday 8/21. Submission link easychair.org/account/signin…
Havent been very active on X, but my PhD student Yuheng Du passed her PhD thesis defense this week! #proudPI #mentorship
Funny but untrue in many steps. There is also a shunt pathway from Industry to academia (I did it). There job for a (good) chair is by no means "handshaking", some of the toughest energy consuming work, seeing the examples around me.
Lana Garmire 🌶 retweeted
In 1960, a quiet woman at the U.S. Food and Drug Administration was handed a routine file. It was for a drug already sold in nearly 50 countries—a sedative called thalidomide, widely marketed as safe for pregnant women.
Most people would have signed off. Frances Oldham Kelsey didn’t.
New to the FDA, she noticed something others had overlooked—or ignored. The data was thin. Reports of nerve damage were buried. The safety claims felt… too clean. While the pharmaceutical company pushed aggressively for approval, sending repeated requests and mounting pressure, Kelsey held her ground. She asked for more studies. Then more. And more.
Behind the scenes, the pressure wasn’t subtle. Drug companies expected quick approvals. Delays meant lost profit. For a young female reviewer in a male-dominated system, saying “no” wasn’t just professional resistance—it was personal risk. She was challenging an industry that wasn’t used to being challenged, especially not by a woman.
Then the truth surfaced.
Across Europe, thousands of babies were being born with devastating deformities—missing limbs, malformed organs—traced back to thalidomide taken during pregnancy. It became one of the worst medical disasters of the 20th century.
Because Kelsey refused to approve it, the United States was largely spared.
Her skepticism saved countless lives.
In 1962, she was awarded the President’s Award for Distinguished Federal Civilian Service by John F. Kennedy—one of the highest honors a civilian could receive. But her impact didn’t stop there. Her stand forced sweeping changes in drug regulation, leading to stricter testing requirements and proof of efficacy before approval. The system became safer because she refused to bend.
She didn’t shout. She didn’t grandstand. She simply refused to compromise when it mattered most.
And that’s what made her dangerous—in the best possible way.
© Women In World History
#archaeohistories
Lana Garmire 🌶 retweeted
KRAS is no longer “undruggable.”
But that’s not the real question.
Why does targeting KRAS not lead to the same outcome across cancers?
Maybe KRAS is trying to teach us something.
Cancer is not just a mutation.
It’s a system.
How that mutation develops,
the microenvironment it lives in,
the pathways it interacts with,
and how resistance emerges…
This is what we need to understand.
Because we now know:
Targeting a single mutation is not enough.
We need to target the network.
@OncoDaily @OncBrothers @myESMO @JCO_ASCO @ASCOPost @Dr_R_Kurzrock @tompowles1 @ilyassahinMD
nature.com/articles/s41698-0…
Lana Garmire 🌶 retweeted
Today’s KRAS win didn’t start today.
It took decades.
Daraxonrasib nearly doubled survival in pancreatic cancer. That’s extraordinary!
But lets zoom out for a sec:
▪️KRAS was called “undruggable.”
▫️NIH quietly poured ~$172M behind it.
▫️Funding grew 9x.
💡One insight (Shokat lab, 2013) changed everything.
This is how breakthroughs are supposed to work:
public money → basic insight
academic labs → first leap
industry → drug + survival curve
Today’s headline has MANY authors.
Congrats to @Revolution_Med and every scientist who stayed on KRAS when it looked impossible.
🎈this is what compounding science truly looks like
= = = = =
Source: NIH RePORTER via @Jori_health
= = = = =
Lana Garmire 🌶 retweeted
🚨🚨🚨
RASOLUTE-302 Ph3 is POSITIVE
"Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW!
AMAZING news for patients with #PancreaticCancer
The RAS Revolution is ON!!
ir.revmed.com/news-releases/…
Plz RT.🤩🤩🤩Free trainee registration for The 10th Annual Translational and Transformative Informatics Symposium (ATTIS) 05/05 2026, with theme “AI in Precision Medicine". @james_y_zou from Stanford will give the keynote.
Abstract submission due by 04/30 for winning awards!
It has been great to see Tay grew from a junior researcher to an independent PI returning to #Thailand, breaking ground for #Bioinformatics there! Best wishes to the new advanture, Tay!
Congratulations to Dr. Tay for successfully defending his PhD on March 27th! 🎓Tay has been working on drug repurposing and women's health with dissertation titled: Precision Medicine with Single-Cell and Spatial Transcriptomics: Applications to Preeclampsia
@GarmireGroup
Lana Garmire 🌶 retweeted
The @NIH has ended continuous submission. The new policy gives two extra calendar weeks from the submission deadline if you have a study section or SEP as a reviewer within 4 weeks before or after a regular deadline, or serve on an NIH advisory council
grants.nih.gov/grants/guide/…
Lana Garmire 🌶 retweeted
I’ve been at a small conference this week, one where the AI people have been presenting early in the week and the domain science people will be presenting later in the week.
At the end of the talks last night, the conversation turned very doomer with all the AI people talking about how well Claude Code or Codex can do hill-climbing AI research and how we (the AI people) are maybe all about to lose our jobs!
The domain science people expressed their shock at this attitude because, though Claude Code can be let loose to complete lots of banal hill-climbing AI research projects, basically no experimental science is hill-climbing or even metric driven. Most scientific fields are about much more taste-driven exploration that is incredibly difficult to make metrics for or to parameterize, and this misunderstanding from the AI community is one of the most damaging things to the realization of great science with AI. Seems like we’re actually pretty far from having AI models do that…
Over the summer, @evijit and I wrote about this (and some other things hindering AI for science) at a bit more length, and today that work is out in Patterns!
So, if you care about these problems and the real challenges in bringing AI to science in the real work, I recommend giving it a read!
Lana Garmire 🌶 retweeted
A 3D multi-compartment assembloid to study
combined immune cell infiltration and cytotoxicity
Contains different compartments with different ECM.
Especially useful to test infiltration and cytotoxicity of CAR T cell therapies.
More here: cell.com/cell-reports-method…
Looking forward to discussing my perspectives of #spatialomics on precision medicine this afternoon.
GCBA Seminar Series announces Lana Garmire, PhD, University of Alabama-Birmingham, Department of Biomedical Informatics and Data Science presenting "Translating Single-cell and Spatial Omics into Precision Medicine." @UNMC_GCBA @UNMC_BISB
Lana Garmire 🌶 retweeted
Contrastive independent component analysis
Scientists constantly face this challenge: you have data from two conditions—patients vs. healthy controls, treated vs. untreated cells, one species vs. another—and you need to find patterns unique to one group. Standard approaches either analyze datasets separately or lump them together, missing the comparative signal entirely.
Contrastive PCA addressed this by subtracting a scaled version of the background covariance from the foreground, then finding principal components of the difference. The problem: researchers must manually choose how much background to subtract. Different choices yield different patterns, requiring parameter sweeps and subjective judgment about which result looks best. Probabilistic contrastive PCA improved the statistical framework but inherited the same tuning burden.
Kexin Wang, Aida Maraj, and Anna Seigal propose contrastive independent component analysis (cICA), which eliminates this guesswork entirely. The key insight: by analyzing fourth-order statistics rather than second-order covariances, the method can determine exactly how much each background pattern contributes to the foreground—no manual tuning required. Moreover, each background component can contribute differently, rather than assuming a single global scaling factor as previous methods do.
The algorithm uses a hierarchical tensor decomposition on fourth-order cumulants, recursively extracting eigenstructure to recover the mixing patterns. This higher-order approach also inherits a fundamental advantage from classical independent component analysis: the patterns become uniquely identifiable, whereas PCA-based methods can only recover them up to rotations.
Results confirm the theoretical advantages translate to practice. On synthetic data, cICA recovers true foreground patterns with over 0.9 cosine similarity, substantially outperforming cPCA and probabilistic cPCA at their best hyperparameter settings. On mouse protein data distinguishing Down syndrome, cICA achieves the highest clustering score. Applied to human versus primate gene expression, the algorithm's top patterns prioritize genes independently validated as human-specific evolutionary drivers.
The practical upshot: when your question is "what's different about this condition?", moving beyond covariance to higher-order structure reveals patterns that simpler methods miss—and does so automatically.
Paper: pnas.org/doi/10.1073/pnas.24…
Lana Garmire 🌶 retweeted
5/10: Disclosure - this is from our lab but one I feel deserves a spot. In collaboration with @IamLinghua, a thorough dissection of spatial heterogeneity & plasticity in primary & metastatic #PancreaticCancer, including differences between organ sites.
nature.com/articles/s41586-0…
Lana Garmire 🌶 retweeted
11/10: Ending with this review by David Tuveson @CSHL aptly titled “Roadmap to Defeat #PancreaticCancer”, summarizing the hallmarks of this disease & where some of the greatest unmet needs are in research. Looking forward to many amazing stories in 2026!
annualreviews.org/content/jo…
Lana Garmire 🌶 retweeted
9/10: The PANORAMA study from USA & Europe showed the added value of #AI for detection of #PancreaticCancer from routine CT scans. The publicly available dataset of scans is a valuable resource for testing algorithms. @ctisus
thelancet.com/journals/lanon…



























